On a preliminary basis, Adamas Pharmaceuticals (ADMS +10.3%) expects Gocovri (amantadine) sales in Q4 and 2019 to be ~$16.3M (+23%) and ~$54.6M (+61%), respectively.
Gocovri prescriptions in Q4 and 2019: 7,160 (+25%) and 25,780 (+66%), respectively.
Final Q4 and 2019 results will be released next month.
The company plans to meet with the FDA in H1 to discuss a registration path for ADS-5102.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.